,Canonical_Smiles,drug_name,drug_type,Label
0,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
1,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
2,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
3,CC(C)c1cccc(C(C)C)c1O,Propofol,CP2CI-Substrate,negative
4,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
5,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
6,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
7,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
8,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
9,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,CP2CI-Substrate,negative
10,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(=O)O,Unoproston,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
11,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
12,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,Capecitabine,2C9-Inhibitor,negative
13,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,Galantamine,2D6-Substrate,negative
14,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,Nicardipine,2E1-Substrate,negative
15,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,-,negative
16,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate,negative
17,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
18,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine,2E1-Inhibitor,negative
19,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
20,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,Naloxone,2C8-Substrate,negative
21,CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@@H]2OC(=CCCCC(=O)O)C[C@@H]21,Epoprostenol,2C9-Substrate,negative
22,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
23,c1ccc([C@H]2CN3CCSC3=N2)cc1,Levamisole,GST-Inducer,positive
24,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor,negative
25,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
26,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
27,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,Prasterone,19A-Substrate,negative
28,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,2E1-Inhibitor,negative
29,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,2E1-Inhibitor,negative
30,CCC(C)(C)OC,tert_amyl_methyl_ether,2E1-Substrate,negative
31,OC(CCC[n+]1ccc(-c2ccc(Cl)cc2)cc1)c1ccc(F)cc1,RHP+,1A2-Substrate,negative
32,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
33,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
34,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
35,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
36,CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,diazinion,2E1-Substrate,negative
37,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
38,C=CC#N,acrylonitrile,2E1-Substrate,negative
39,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate,negative
40,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
41,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,Nandrolone,GST-Inducer,positive
42,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
43,C=CCc1cc(OC)c2c(c1)OCO2,myristicin,1A2-Substrate,negative
44,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
45,Fc1cccc2c1OC1CNCC1O2,Fluparoxan,-,negative
46,C[N+](C)(C)C[C@H](O)CC(=O)[O-],Levocarnitine,2E1-Substrate,negative
47,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
48,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
49,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,Amiodarone,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
50,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
51,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,Budesonide,SUL-Substrate,negative
52,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
53,N=C(N)N1CCc2ccccc2C1,Debrisoquine,2D6-Substrate,negative
54,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@@H]3C[C@@H]12,Tetracycline,GST-Inhibitor,negative
55,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
56,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
57,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
58,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
59,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
60,CC1=CC(=O)C=C2CCC3C4CCC(=O)C4(C)CCC3C12C,Atamestane,-,negative
61,CCNc1nc(NC(C)C)nc(SC)n1,ametryne,2C19-Substrate,negative
62,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,Bexarotene,-,negative
63,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Pimecrolimus,3A4-Substrate,negative
64,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
65,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,Zafirlukast,2E1-Inhibitor,negative
66,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,Aripiprazole,P450_HFLA-Substrate,negative
67,CC(C)CC(O)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1,bortezomib_M1_M2,2C19-Substrate,negative
68,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
69,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,Cyproheptadin,UGT-Substrate,negative
70,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
71,C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,Tiaprofenic Acid,GST-Inhibitor,negative
72,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
73,C/C=C\C,cis_2_butene,2E1-Substrate,negative
74,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
75,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,UGT-Substrate,negative
76,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
77,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor,negative
78,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Glycyrrhizic Acid,P450_HFLA-Inducer,negative
79,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
80,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
81,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
82,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@H](C(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCCCN)NC1=O,Somatostatin,2D6-Inhibitor,negative
83,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
84,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
85,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
86,O=C(NC1CCSC2CCCC(C(=O)O)N2C1=O)C(S)Cc1ccccc1,Omapatrilat,-,negative
87,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
88,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,Estazolam,3A4-Substrate,negative
89,CN[C@@H](C)[C@@H](O)c1ccccc1,Pseudoephedrine,SUL-Substrate,negative
90,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
91,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
92,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,Venlafaxine,2D6-Inhibitor,negative
93,Cc1c(F)c(N2CCN[C@@H](C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,Grepafloxacin,-,negative
94,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vincristine,P450_HFLA-Substrate,negative
95,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
96,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,Cefotiam,Solute_carrier_family_22_member_8-Substrate,negative
97,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate,negative
98,CC(C)NC[C@H](O)COc1cccc2ccccc12,propranolol_S,2D6-Substrate,negative
99,CCN(CC)N=O,NN_diethyl_nitrosoamine,2E1-Substrate,negative
100,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
101,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
102,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,Sulfasalazine,-,negative
103,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
104,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
105,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
106,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
107,C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,Tiotropium Bromide,2D6-Substrate,negative
108,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
109,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
110,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
111,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
112,CN1C(=O)CC(=O)N(c2ccc(O)cc2)c2cc(Cl)ccc21,4prime_hydroxy_clobazam,2C19-Substrate,negative
113,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
114,NCC1(CC(=O)O)CCCCC1,Gabapentin,GST-Inducer,positive
115,Cc1ccsc1-c1ccc([C@H](C)C(=O)O)cc1,S_MTPPA,2C9-Substrate,negative
116,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,2E1-Substrate,negative
117,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
118,COc1ccc(C(C)C)cc1CNC1C2CCN(CC2)C1C(c1ccccc1)c1ccccc1,Ezlopitant,2D6-Substrate,negative
119,NC(=O)c1cnccn1,Pyrazinamide,1A2-Substrate,negative
120,CCC[C@H](N[C@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,Perindopril,GST-Inhibitor,negative
121,CCOP(=S)(OCC)SCCSCC,disulfoton,2D6-Substrate,negative
122,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
123,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
124,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer,negative
125,COc1ccc([C@H](CN(C)C)C2(O)CCCCC2)cc1,venlafaxine_R,2D6-Substrate,negative
126,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
127,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
128,CCOc1ccc(NC(C)=O)cc1,Phenacetin,2E1-Substrate,negative
129,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
130,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,Teriparatide,24A-Inhibitor,negative
131,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
132,CCCC(CCC)C(=O)O,Valproic Acid,GST-Inducer,positive
133,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,Technetium (99mTc) Mebrofenin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
134,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
135,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
136,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor,negative
137,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,-,negative
138,Cl,Hydrochloric Acid,2D6-Inhibitor,negative
139,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
140,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
141,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
142,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
143,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
144,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
145,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
146,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate,negative
147,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
148,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,Fesoterodine,2D6-Substrate,negative
149,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
150,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,2E1-Substrate,negative
151,CCCCOc1ccc2ccc(=O)oc2c1,7_butoxy_coumarin,3A4-Substrate,negative
152,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
153,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
154,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
155,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate,negative
156,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
157,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Cortisone,SUL-Inhibitor,negative
158,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
159,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
160,CNCc1cc(=O)oc2cc(OC)ccc12,MMAMC,2D6-Substrate,negative
161,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
162,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
163,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
164,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
165,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
166,O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,Fluorescein,Solute_carrier_family_22_member_6-Substrate,negative
167,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,DMXAA,1A2-Substrate,negative
168,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
169,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate,negative
170,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,negative
171,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
172,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,indiplon,1A2-Substrate,negative
173,Oc1ccccc1,Phenol,2E1-Substrate,negative
174,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolphthalein,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
175,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Hydroxyprogesterone,Steroid_21_hydroxylase_21_OHase-Substrate,negative
176,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,Astemizole,P450_HFLA-Substrate,negative
177,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
178,C=Cc1ccccc1,styrene,2E1-Substrate,negative
179,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
180,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
181,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Fosamprenavir,2C19-Inhibitor,negative
182,O=[P@]1(NCCCl)OCCCN1CCCl,Ifosfamide,CP2CI-Substrate,negative
183,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
184,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
185,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
186,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
187,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,P450_HFLA-Substrate,negative
188,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
189,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
190,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,P450_HFLA-Substrate,negative
191,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,-,negative
192,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,-,negative
193,C=CC(=C)C,isoprene,2E1-Substrate,negative
194,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
195,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
196,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,positive
197,CN1C(=O)CCC1c1cccnc1,Cotinine,-,negative
198,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
199,COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Omeprazole,CP2CI-Substrate,negative
200,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,Cisapride,GST-Inducer,positive
201,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
202,CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1,Gepirone,2D6-Substrate,negative
203,Nc1ccc(C(=O)NCC(=O)O)cc1,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate,negative
204,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
205,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,2E1-Inhibitor,negative
206,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,positive
207,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
208,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
209,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
210,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
211,CCOC(C)(C)C,ethyl_tert_butyl_ether,2E1-Substrate,negative
212,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
213,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
214,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
215,OC(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,reduced_haloperidol,3A4-Substrate,negative
216,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,Caspofungin,3A4-Inhibitor,negative
217,CCOCC,Diethyl Ether,2E1-Inducer,negative
218,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Doxycycline,-,negative
219,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
220,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
221,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,Raloxifene,19A-Inhibitor,negative
222,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
223,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
224,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Escitalopram,2D6-Substrate,negative
225,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
226,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],Nifedipine,2E1-Inhibitor,negative
227,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
228,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
